Wuhan Thalys Med Tech Co Ltd Total Assets
Wuhan Thalys Med Tech Co Ltd total assets. Based on the latest financial reports, Wuhan Thalys Med Tech Co Ltd (603716) holds total assets worth CN¥1.59 Billion CNY (≈ $232.78 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Wuhan Thalys Med Tech Co Ltd stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Wuhan Thalys Med Tech Co Ltd (2011–2025)
Total assets of Wuhan Thalys Med Tech Co Ltd from 2011 to 2025. This chart illustrates how Wuhan Thalys Med Tech Co Ltd's total assets have evolved over time, based on quarterly financial data. See Wuhan Thalys Med Tech Co Ltd stock quote for real-time trading data and today's change.
Wuhan Thalys Med Tech Co Ltd - Asset Composition Analysis
Wuhan Thalys Med Tech Co Ltd Total Assets Breakdown (December 2025)
Wuhan Thalys Med Tech Co Ltd total assets breakdown as of December 2025. Wuhan Thalys Med Tech Co Ltd's total assets of CN¥1.59 Billion consist of 68.7% current assets and 31.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.3% |
| Accounts Receivable | CN¥734.08 Million | 40.7% |
| Inventory | CN¥223.38 Million | 12.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥30.36 Million | 1.7% |
| Goodwill | CN¥15.09 Million | 0.8% |
Asset Composition Trend (2011–2025)
This chart illustrates how Wuhan Thalys Med Tech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Wuhan Thalys Med Tech Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wuhan Thalys Med Tech Co Ltd's current assets represent 68.7% of total assets in 2025, a decrease from 79.6% in 2011.
- Cash Position: Cash and equivalents constituted 7.3% of total assets in 2025, down from 20.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 40.7% of total assets.
Wuhan Thalys Med Tech Co Ltd Competitors by Total Assets
Key competitors of Wuhan Thalys Med Tech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.52 Billion |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
|
Cryosite Ltd
AU:CTE
|
Australia | AU$26.55 Million |
Wuhan Thalys Med Tech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.90 | 1.73 | 2.08 |
| Quick Ratio | 1.55 | 1.43 | 1.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥484.61 Million | CN¥624.07 Million | CN¥1.55 Billion |
Wuhan Thalys Med Tech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Wuhan Thalys Med Tech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.49 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | -36.3% |
| Total Assets | CN¥1.80 Billion |
| Market Capitalization | $497.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values Wuhan Thalys Med Tech Co Ltd's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Wuhan Thalys Med Tech Co Ltd's assets decreased by 36.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Wuhan Thalys Med Tech Co Ltd (2011–2025)
The table below shows the annual total assets of Wuhan Thalys Med Tech Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.80 Billion ≈ $263.75 Million |
-36.31% |
| 2024-12-31 | CN¥2.83 Billion ≈ $414.13 Million |
-15.31% |
| 2023-12-31 | CN¥3.34 Billion ≈ $489.01 Million |
-15.34% |
| 2022-12-31 | CN¥3.95 Billion ≈ $577.64 Million |
-8.06% |
| 2021-12-31 | CN¥4.29 Billion ≈ $628.28 Million |
+9.91% |
| 2020-12-31 | CN¥3.91 Billion ≈ $571.62 Million |
+29.91% |
| 2019-12-31 | CN¥3.01 Billion ≈ $440.03 Million |
+16.43% |
| 2018-12-31 | CN¥2.58 Billion ≈ $377.95 Million |
+64.57% |
| 2017-12-31 | CN¥1.57 Billion ≈ $229.65 Million |
+43.65% |
| 2016-12-31 | CN¥1.09 Billion ≈ $159.86 Million |
+64.71% |
| 2015-12-31 | CN¥663.27 Million ≈ $97.06 Million |
+23.38% |
| 2014-12-31 | CN¥537.57 Million ≈ $78.66 Million |
+22.79% |
| 2013-12-31 | CN¥437.79 Million ≈ $64.06 Million |
+12.60% |
| 2012-12-31 | CN¥388.80 Million ≈ $56.89 Million |
+23.76% |
| 2011-12-31 | CN¥314.16 Million ≈ $45.97 Million |
-- |
About Wuhan Thalys Med Tech Co Ltd
Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis sy… Read more